Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:MDWD NASDAQ:MNMD NASDAQ:SANA NASDAQ:TBPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMDWDMediWound$17.84-6.4%$18.58$14.14▼$22.50$205.99M0.25149,122 shs208,497 shsMNMDMind Medicine (MindMed)$9.44-2.2%$9.28$4.70▼$11.02$718.27M2.481.08 million shs960,544 shsSANASana Biotechnology$3.22-5.3%$3.72$1.26▼$7.30$765.74M1.884.06 million shs3.00 million shsTBPHTheravance Biopharma$14.30+4.4%$12.39$7.88▼$14.55$689.95M0.05527,745 shs848,891 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMDWDMediWound0.00%+9.52%-3.93%-12.63%+4.27%MNMDMind Medicine (MindMed)0.00%+2.39%-2.88%+31.66%+57.60%SANASana Biotechnology0.00%+8.78%-6.12%+24.32%-35.47%TBPHTheravance Biopharma0.00%+2.51%+10.51%+33.77%+76.54%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeMDWDMediWound$17.84-6.4%$18.58$14.14▼$22.50$205.99M0.25149,122 shs208,497 shsMNMDMind Medicine (MindMed)$9.44-2.2%$9.28$4.70▼$11.02$718.27M2.481.08 million shs960,544 shsSANASana Biotechnology$3.22-5.3%$3.72$1.26▼$7.30$765.74M1.884.06 million shs3.00 million shsTBPHTheravance Biopharma$14.30+4.4%$12.39$7.88▼$14.55$689.95M0.05527,745 shs848,891 shs10 Best Stocks to Own: Fall 2025Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Fall 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceMDWDMediWound0.00%+9.52%-3.93%-12.63%+4.27%MNMDMind Medicine (MindMed)0.00%+2.39%-2.88%+31.66%+57.60%SANASana Biotechnology0.00%+8.78%-6.12%+24.32%-35.47%TBPHTheravance Biopharma0.00%+2.51%+10.51%+33.77%+76.54%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceMDWDMediWound 2.80Moderate Buy$32.2580.77% UpsideMNMDMind Medicine (MindMed) 3.22Buy$24.71161.80% UpsideSANASana Biotechnology 3.00Buy$8.00148.45% UpsideTBPHTheravance Biopharma 3.60Strong Buy$23.0060.84% UpsideCurrent Analyst Ratings BreakdownLatest MDWD, SANA, TBPH, and MNMD Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails9/12/2025TBPHTheravance BiopharmaB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageBuy$28.009/11/2025TBPHTheravance BiopharmaB. RileySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy8/19/2025MDWDMediWoundZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeStrong-Buy ➝ Hold8/15/2025TBPHTheravance BiopharmaZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeHold ➝ Strong-Buy8/4/2025MNMDMind Medicine (MindMed)OppenheimerSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOutperform$25.008/1/2025MNMDMind Medicine (MindMed)Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$20.007/3/2025SANASana BiotechnologyMorgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingInitiated CoverageOverweight$12.006/27/2025TBPHTheravance BiopharmaBTIG ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$24.00 ➝ $25.006/24/2025SANASana BiotechnologyJMP SecuritiesSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingMarket Outperform$5.006/17/2025TBPHTheravance BiopharmaJones TradingSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeStrong-Buy$24.00(Data available from 9/14/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookMDWDMediWound$20.22M9.54N/AN/A$2.89 per share6.17MNMDMind Medicine (MindMed)N/AN/AN/AN/A$3.21 per shareN/ASANASana BiotechnologyN/AN/AN/AN/A$1.12 per shareN/ATBPHTheravance Biopharma$64.38M11.19N/AN/A$3.57 per share4.01Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateMDWDMediWound-$30.22M-$2.64N/AN/AN/A-142.18%-96.71%-39.73%11/25/2025 (Estimated)MNMDMind Medicine (MindMed)-$108.68M-$1.53N/AN/AN/AN/A-50.24%-39.41%11/6/2025 (Estimated)SANASana Biotechnology-$266.76M-$1.06N/AN/AN/AN/A-91.96%-43.07%11/14/2025 (Estimated)TBPHTheravance Biopharma-$56.42M$0.2459.5840.86N/A16.88%6.93%3.52%11/11/2025 (Estimated)Latest MDWD, SANA, TBPH, and MNMD EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/14/2025Q2 2025MDWDMediWound-$0.55-$1.23-$0.68-$1.23$5.68 million$5.71 million8/11/2025Q2 2025SANASana Biotechnology-$0.20-$0.16+$0.04-$0.39N/AN/A7/31/2025Q2 2025MNMDMind Medicine (MindMed)-$0.38-$0.50-$0.12-$0.50N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthMDWDMediWoundN/AN/AN/AN/AN/AMNMDMind Medicine (MindMed)N/AN/AN/AN/AN/ASANASana BiotechnologyN/AN/AN/AN/AN/ATBPHTheravance BiopharmaN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioMDWDMediWoundN/A1.481.35MNMDMind Medicine (MindMed)0.224.984.98SANASana BiotechnologyN/A2.472.47TBPHTheravance BiopharmaN/A6.706.70Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipMDWDMediWound46.83%MNMDMind Medicine (MindMed)27.91%SANASana Biotechnology88.23%TBPHTheravance Biopharma99.10%Insider OwnershipCompanyInsider OwnershipMDWDMediWound9.20%MNMDMind Medicine (MindMed)2.45%SANASana Biotechnology30.10%TBPHTheravance Biopharma6.90%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableMDWDMediWound8010.81 million9.81 millionOptionableMNMDMind Medicine (MindMed)4076.09 million74.22 millionOptionableSANASana Biotechnology380237.81 million166.23 millionOptionableTBPHTheravance Biopharma11050.36 million46.89 millionOptionableMDWD, SANA, TBPH, and MNMD HeadlinesRecent News About These CompaniesTheravance Biopharma (NASDAQ:TBPH) Shares Up 4.6% - Should You Buy?September 14 at 12:11 PM | marketbeat.comTheravance Biopharma, Inc. (NASDAQ:TBPH) Receives Average Rating of "Buy" from BrokeragesSeptember 14 at 8:19 AM | marketbeat.comB. Riley Initiates Coverage on Theravance Biopharma (NASDAQ:TBPH)September 14 at 8:14 AM | marketbeat.comTheravance Biopharma, Inc. $TBPH Shares Sold by Jacobs Levy Equity Management Inc.September 14 at 3:25 AM | marketbeat.comB. Riley Begins Coverage on Theravance Biopharma (NASDAQ:TBPH)September 13 at 3:45 AM | americanbankingnews.com46,972 Shares in Theravance Biopharma, Inc. $TBPH Bought by Cubist Systematic Strategies LLCSeptember 13 at 3:24 AM | marketbeat.comB. Riley Securities Initiates Coverage of Theravance Biopharma (TBPH) with Buy RecommendationSeptember 12 at 5:46 PM | msn.comTheravance Biopharma initiated with a Buy at B. RileySeptember 12 at 12:46 PM | msn.comTheravance Bio (TBPH) Up 9.8% Since Last Earnings Report: Can It Continue?September 11 at 12:30 PM | zacks.comInvesco Ltd. Sells 23,515 Shares of Theravance Biopharma, Inc. $TBPHSeptember 10, 2025 | marketbeat.comQ3 Earnings Estimate for TBPH Issued By Zacks ResearchSeptember 7, 2025 | marketbeat.comTheravance Biopharma, Inc. $TBPH Shares Bought by PDT Partners LLCSeptember 6, 2025 | marketbeat.comResearch Analysts Set Expectations for TBPH Q3 EarningsSeptember 6, 2025 | americanbankingnews.comTheravance Biopharma (NASDAQ:TBPH) Hits New 12-Month High - Should You Buy?September 4, 2025 | marketbeat.comTheravance Biopharma to Present at the H.C. Wainwright 27th Annual Global Investment ConferenceSeptember 2, 2025 | prnewswire.comWellington Management Group LLP Sells 43,062 Shares of Theravance Biopharma, Inc. $TBPHSeptember 2, 2025 | marketbeat.comRussell Investments Group Ltd. Has $429,000 Stake in Theravance Biopharma, Inc. $TBPHSeptember 2, 2025 | marketbeat.comVanguard Group Inc. Grows Stake in Theravance Biopharma, Inc. $TBPHSeptember 1, 2025 | marketbeat.comTheravance Biopharma, Inc. $TBPH Shares Sold by Deutsche Bank AGSeptember 1, 2025 | marketbeat.comNuveen LLC Acquires Shares of 374,952 Theravance Biopharma, Inc. $TBPHAugust 30, 2025 | marketbeat.comTheravance Biopharma (NASDAQ:TBPH) Stock Price Crosses Above 50 Day Moving Average - Here's WhyAugust 28, 2025 | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeMDWD, SANA, TBPH, and MNMD Company DescriptionsMediWound NASDAQ:MDWD$17.84 -1.22 (-6.40%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$17.86 +0.02 (+0.08%) As of 09/12/2025 05:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units. The company also develops EscharEx, which has completed Phase II clinical trials for the debridement of chronic and other hard-to-heal wounds; and MW005, which is in phase I/II for the treatment of low-risk basal cell carcinoma. MediWound Ltd. was incorporated in 2000 and is headquartered in Yavne, Israel.Mind Medicine (MindMed) NASDAQ:MNMD$9.44 -0.21 (-2.18%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$9.45 +0.01 (+0.15%) As of 09/12/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Mind Medicine (MindMed) Inc., a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company's lead product candidates include MM-120, which is in phase 2 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and MM-402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase I clinical trials for the treatment of core symptoms of autism spectrum disorder. Mind Medicine (MindMed) Inc. is headquartered in New York, New York.Sana Biotechnology NASDAQ:SANA$3.22 -0.18 (-5.29%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$3.22 -0.01 (-0.16%) As of 09/12/2025 07:53 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sana Biotechnology, Inc., a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others. The company's product candidates include SC291 that is used as allogeneic cell therapies for hematologic malignancies; ARDENT for a potential treatment for non-Hodgkin's lymphoma, and chronic lymphoblastic leukemia; GLEAM, to treat multiple autoimmune disorders that involve production of autoimmune antibodies, including lupus nephritis, extrarenal lupus, antineutrophil cytoplasmic antibody -associated vasculitis, and others. It is developing SC262 to treat patients with relapsed and/or refractory B-cell malignancies; SC255 for multiple myeloma treatment; SC379, a therapy for patients with certain central nervous system disorders healthy allogeneic glial progenitor cells; SC451, a product candidate to treat diabetes, with an initial focus on type 1 diabetes mellitus; and UP421 that reduces long-term exogenous insulin dependence. The company has an option and license agreement with Beam Therapeutics Inc. for use of Beam's proprietary CRISPR Cas12b nuclease editing technology to research, develop, and commercialize engineered cell therapy products; and a license agreement with Harvard College to access certain intellectual property for the development of hypoimmune-modified cells. The company was formerly known as FD Therapeutics, Inc. and changed its name to Sana Biotechnology, Inc. in September 2018. Sana Biotechnology, Inc. was incorporated in 2018 and is headquartered in Seattle, Washington.Theravance Biopharma NASDAQ:TBPH$14.30 +0.60 (+4.38%) Closing price 09/12/2025 04:00 PM EasternExtended Trading$14.46 +0.16 (+1.11%) As of 09/12/2025 07:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Theravance Biopharma, Inc. is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology. In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world. The Company applies organ-selective expertise to target disease biologically, to discover and develop medicines that may expand the therapeutic index with the goal of maximizing efficacy and limiting systemic side effects. These efforts leverage years of experience in developing lung-selective medicines to treat respiratory disease, including FDA-approved YUPELRI® (revefenacin) inhalation solution indicated for the maintenance treatment of patients with chronic obstructive pulmonary disease (COPD). Its pipeline of internally discovered programs is targeted to address significant patient needs. Theravance Biopharma has an economic interest in potential future payments from Glaxo Group Limited or one of its affiliates (GSK) pursuant to its agreements with Innoviva, Inc. relating to certain programs, including TRELEGY. For more information, please visit www.theravance.com. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 09/08 - 09/12 Meta's $600B U.S. Investment: Bearish or Bullish for Shares? Football Season Is Here and DraftKings Stock Is Surging RH Stock Slides After Mixed Earnings and Tariff Concerns Post Onum Deal: Is CrowdStrike Ready to Rebound After 16% Drop? Chewy’s September Pullback: Is It Your Time to Buy? It’s Time to Buy the Dip in Kroger Stock Price Is Coupang the Next MercadoLibre? A Playbook for Global Dominance Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
